Ben Enejo
Partner
Ben assists top healthcare clients across Regulatory & Medical Affairs functions, as well as Commercial Strategy & Operations, with a specialty in business transformation and operational excellence initiatives.
Areas of Focus
Education
Past Experience
Ben is a Partner at Arthur D. Little, based in our Boston office, and a member of our global Healthcare & Life Sciences Practice.
Ben is an experienced management consultant and industry expert having worked with various global biopharmaceutical companies on strategies to accelerate the development of new medicines through to commercialization. Particular areas of expertise include clinical trial acceleration, R&D transformation including advanced technology application, increasing success for rare disease drug development and launch, patient and drug safety, and quality and compliance excellence.
Ben holds an MBA with other qualifications in Molecular Medicine, Pharmacology and Physiology, and Program management.
Accelerating cures
Why patient centricity is key to long-term pharma company success
The future of pharmacovigilance
CAR-T on site: Forgoing the extra mile
Managing clinical trials during COVID-19 and beyond
Maximizing the rare chance of launch success with orphan drugs
The BIG patent expiry question: Why sink when you can sail?
Ben is a Partner at Arthur D. Little, based in our Boston office, and a member of our global Healthcare & Life Sciences Practice.
Ben is an experienced management consultant and industry expert having worked with various global biopharmaceutical companies on strategies to accelerate the development of new medicines through to commercialization. Particular areas of expertise include clinical trial acceleration, R&D transformation including advanced technology application, increasing success for rare disease drug development and launch, patient and drug safety, and quality and compliance excellence.
Ben holds an MBA with other qualifications in Molecular Medicine, Pharmacology and Physiology, and Program management.
Accelerating cures
Why patient centricity is key to long-term pharma company success
The future of pharmacovigilance
CAR-T on site: Forgoing the extra mile
Managing clinical trials during COVID-19 and beyond
Maximizing the rare chance of launch success with orphan drugs
The BIG patent expiry question: Why sink when you can sail?
More About Ben
- Cranfield School of ManagementMaster of Business Administration
- Cranfield UniversityM.Sc. Molecular Medicine
- Nottingham Trent UniversityB.Sc. Physiology & Pharmacology
- PA Consulting GroupHealthcare Management Consultant
- Astra ZenecaPatient Safety Advisor
- Janssen Pharmaceuticals (Johnson & Johnson)Pharmacovigilance Associate
- Medical Gases LtdSales Engineer (Business Development)